Six pivotal trials are evaluating novel therapies targeting CNS-compartmentalized inflammation to address the unmet clinical need in progressive multiple sclerosis.
Emerging therapies for progressive multiple sclerosis (PMS) increasingly target CNS-compartmentalized inflammation driving progression independent of relapse activity. Six pivotal trials are evaluating Bruton's tyrosine kinase inhibitors, CD40-CD40L blockade, and CD19-directed CAR-T cells. Together, these studies may establish mechanism-based strategies to modulate microglia and B cell pathology, redefining treatment of progression and addressing a major unmet clinical need.
Rocca et al. (Thu,) studied this question.